Plain-English translation of NCT05830500 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a real-world study looking at how well a medication called Anlotinib works for people with advanced medullary thyroid cancer—a rare type of thyroid cancer that has spread and cannot be surgically removed. Researchers will track how the medication affects tumor growth and causes side effects in a broad group of patients. The study will also collect information from similar patients who do not take this medication, so doctors can compare how people respond to treatment versus observation alone.
Medullary thyroid cancer is a rare and serious disease, and doctors need to understand how well this medication works in everyday patients—not just in controlled research settings. By studying real-world outcomes, researchers can learn whether the treatment helps people live longer and what side effects to watch for.
You likely qualify if…
You likely don't qualify if…
If you join the treatment group, you will take the medication by mouth—12 mg once daily for 2 weeks, then take 1 week off, repeating this 3-week cycle. If you join the observation group, you will not take the medication but researchers will collect your medical records and track your health over time. Both groups will have regular clinic visits to measure your tumors, check your blood work, and monitor for side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China